New therapies for heart failure: is thalidomide the answer? by Davey, P, Ashrafian, H

“…The principle therapeutic action of thalidomide appears to be reduction of TNF-alpha levels. …”

Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. by Schütt, P, Ebeling, P, Buttkereit, U, Brandhorst, D, Opalka, B, Hoiczyk, M, Flasshove, M, Hense, J, Bojko, P, Metz, K, Moritz, T, Seeber, S, Nowrousian, MR

“…Thalidomide (400 mg/d) was combined with bolus injections of vincristine and epirubicin and oral dexamethasone (VED). …”

In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment. by Schütt, P, Buttkereit, U, Brandhorst, D, Lindemann, M, Schmiedl, S, Grosse-Wilde, H, Seeber, S, Nowrousian, MR, Opalka, B, Moritz, T

“…In patients treated with thalidomide, however, it remains to be seen whether the reduced expression of co-stimulatory molecules has functional relevance.…”

Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with transplant‐ineligible multiple myeloma: A network meta‐analysis by Piechotta, V, Jakob, T, Langer, P, Monsef, I, Scheid, C, Estcourt, L, Ocheni, S, Theurich, S, Kuhr, K, Scheckel, B, Adams, A, Skoetz, N

“…First‐line treatment for transplant‐ineligible individuals consists of multiple drug combinations of bortezomib (V), lenalidomide (R), or thalidomide (T). However, access to these medicines is restricted in many countries worldwide. …”

Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival. by Schütt, P, Ebeling, P, Buttkereit, U, Brandhorst, D, Opalka, B, Poser, M, Müller, S, Flasshove, M, Moritz, T, Seeber, S, Nowrousian, MR

“…Twenty-two patients received thalidomide in combination with dexamethasone and seven patients thalidomide alone. …”

Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor alpha antibody. by Travis, S, Czajkowski, M, McGovern, D, Watson, R, Bell, A

“…Treatment with prednisolone, methyl prednisolone, and thalidomide in one and prednisolone, colchicine, and cyclosporin in the other was ineffective. …”

Reproductive medicine: still more ART than science? by Wilkinson, J, Bhattacharya, S, Duffy, J, Kamath, M, Marjoribanks, J, Repping, S, Vail, A, Van Wely, M, Farquhar, C

“…As a specialty, we have relied on investigations including X‐ray pelvimetry and antenatal stress tests, subjected innumerable women to stilboestrol and thalidomide, and have performed routine episiotomy in all primigravid women 1,. …”

Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. by Schütt, P, Brandhorst, D, Stellberg, W, Poser, M, Ebeling, P, Müller, S, Buttkereit, U, Opalka, B, Lindemann, M, Grosse-Wilde, H, Seeber, S, Moritz, T, Nowrousian, MR

“…Conventional-dose chemotherapy resulted in significantly reduced CD4+ and even further decline of CD4+/CD45RO+ and CD19+ cells, most notably in relapsed patients. Additional thalidomide treatment had no significant effects on these parameters. …”

Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma by Song, Y, Park, P, Wu, L, Ray, A, Picaud, S, Li, D, Wimalasena, V, Du, T, Filippakopoulos, P, Anderson, K, Qi, J, Chauhan, D

“…WL40 was synthesized by linking the Rpn13 covalent inhibitor RA190 with the cereblon (CRBN) binding ligand thalidomide. We show that WL40 binds to both Rpn13 and CRBN and triggers degradation of cellular Rpn13, and is therefore first-in-class in exploiting a covalent inhibitor for the development of degraders. …”

Everolimus therapy for progressive adrenocortical cancer by Fraenkel, M, Gueorguiev, M, Barak, D, Salmon, A, Grossman, AB, Gross, D

“…All had progressive disease (PD) despite treatment with mitotane and other treatment modalities (etoposide, doxorubicin, cis-platinum in 3/4 patients, further streptozotocin + 5-FU in 1/4 patients, further thalidomide therapy in 2/4 patients; 1 patient progressed on an IGF-R antagonist). …”

Everolimus therapy for progressive adrenocortical cancer. by Fraenkel, M, Gueorguiev, M, Barak, D, Salmon, A, Grossman, AB, Gross, D

“…All had progressive disease (PD) despite treatment with mitotane and other treatment modalities (etoposide, doxorubicin, cis-platinum in 3/4 patients, further streptozotocin + 5-FU in 1/4 patients, further thalidomide therapy in 2/4 patients; 1 patient progressed on an IGF-R antagonist). …”

Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. by Haynes, R, Read, S, Collins, G, Darby, S, Winearls, C

“…The advent of efficacious low toxicity chemotherapy (such as thalidomide and bortezomib) and new dialysis techniques to remove free light chains may radically alter the outcome of this group of patients.…”

A bump and hole approach to the development of selective degrons by Brennan, PJ

“…Traditional IMiDs, such as thalidomide, lenalidomide and pomalidomide, are unsuitable for target validation due to off-target degradation of transcription factors IKZF1 and IKZF3, as well as other endogenous proteins.…”

The 5q- syndrome. by Giagounidis, A, Germing, U, Wainscoat, J, Boultwood, J, Aul, C

“…The most promising therapeutic approach is the novel thalidomide analogue CC5013 that is currently evaluated in an international phase II study.…”